Мупироцин: уникальный антибиотик для местного применения

Клиническая Микробиология и Антимикробная Химиотерапия. 1999; 1(1):57-65

​ Богданович Т.М., Страчунский Л.С.
мупироцин местная антибиотикотерапия MRSA антибиотикопрофилактика
Раздел
Новое о препаратах
Тип
Журнальная статья
Публикация
Клиническая Микробиология и Антимикробная Химиотерапия. 1999; 1(1):57-65

Аннотация

Начиная с 1867 г., когда Джозеф Листер впервые использовал местные аппликации карболовой кислоты при лечении открытого перелома кости, антисептики получили широкое распространение в клинической практике. При этом в отличие от препаратов для системного применения их редко изучали тщательно. Рост интереса к антимикробным препаратам для местного применения был вызван разработкой и внедрением в практику нового антибиотика – мупироцина.

  • 1. Barret S.P. The value of nasal mupirocin in containing anoutbreak of methicillin resistant Staphylococcus aureus in an orthopedic ward //J.Hosp.Infect.– 1990.– Vol.15.– P.137 –142.
  • 2. Barton L.L., Friedman A.D., Sharkey A.M. Impetigo contagiosa. III. Comparative efficacy of oral erythromycin and topical mupirocin //Pediatr.Dermatol.–1989.– Vol.6.– P.134 –138.
  • 3. Bass J.W., Chan D.S., Creamer K.M.et al. Comparison of oral cephalexin, topical mupirocin and topical bacitracin for treatment of impetigo //Pediatr.Infect.Dis.J.– 1997. –Vol.16,N 7.–P.708 –709.
  • 4. Berry V. et al. In vivo efficacy of novel topical pleuromutilins, SB 247386 and SB 268091 //39th ICAAC.– 1999.– Abstract 1702.– P.337.
  • 5. Bloom B.S., Fendrick A.M., Chernew M.E., Patel P. Clinical and economic effects of mupirocin calcium on preventing Staphylococcus aureus infection in hemodialysis patients:a decision analysis //Amer.J.Kidney.Dis. –1996.– Vol.27,N 5.–P.687 –694.
  • 6. Booth J.H., Benrimoj S.I. Mupirocin in the treatment of impetigo //Int.J.Dermatol.–1992.– Vol.31.– P.1 –9.
  • 7. Bork k., Brauers J., Kresken M. Efficacy and safety of 2% mupirocin ointment in the treatment of primary and secondary skin infections – an open multicentre trial // Brit.J.Clin.Pract.– 1989.– Vol.43.– P.284 –288.
  • 8. Bradley S.F. Effectiveness of mupirocin in the control of methicillin resistant Staphylococcus aureus //Infect. Med.– 1993.– Vol.10.– P.23 –31.
  • 9. Bruns D.E., Herold D.A., Rodeheaver G.T., Edlich R.F. Polyethylene glycol intoxication in burn patients // Burns.– 1992.– Vol.9.– P.49 –52.
  • 10. Buchvald J. An evaluation of topical mupirocin in moderately severe primary and secondary skin infections //J.Int.Med.Res.– 1988.– Vol.16.– P.66 –70.
  • 11. Casewell M.W., Hill R.L.R. Elimination of nasal carriage of Staphylococcus aureus with mupirocin ("pseudomonic acid")–a controlled study //J.Antimicrob.Chemother. –1986.– Vol.17.– P.365 –372.
  • 12. Casewell M.W., Hill R.L.D.Mupirocin ("pseudomonic acid") a promising new topical antimicrobial agent //J.Antimicrob.Chemother.–1987.– Vol.19.– P.1 –5.
  • 13. Cederna J.E., Terpenning M.S., Ensberg M. Staphylococcus aureus nasal colonization in a nursing home: eradication with mupirocin //Infect.Cont.Hosp.Epidemiol.–1990.– Vol.11.– P.13 –16.
  • 14. Chain E.B., Mellows G. Pseudomonic acid.Part I. The structure of pseudomonic acid A,a novel antibiotic produced by Pseudomonas fluorescens //J.Chem.Soc.Perkin Transactions.–1977.– Vol.1.– P.294 –309.
  • 15. Colin M., Avon P. Comparative double blind evaluation of a new topical antibacterial agent, mupirocin, compared with placebo in the treatment of skin and soft tissue infections //Pharmatherapeutica.–1988.–Vol.5.– P.198 –203.
  • 16. Connoly S., Noble W.C., Phillips I. Mupirocin resistance in coagulase negative staphylococci //J.Med.Microbiol. –1993.– Vol.39.– P.450 –453.
  • 17. Cookson B.D., Farrelly H., Stapleton P.et al. Transferable resistance to triclosan in MRSA //Lancet.– 1991.– Vol.337.– P.1548 –1549.
  • 18. Cookson B.D., Lacey R.W., Noble W.C.et al. Mupirocin resistant Staphylococcus aureus //Lancet.– 1990.– Vol.326.– P 1095 –1096.
  • 19. Dariouche R., Wright C., Hamill R. Eradication of colonization by methicillin resistant Staphylococcus aureus by using oral minocycline rifampin and topical mupirocin //Antimicrob.Agent.Chemother.–1991.– Vol.35.– P.1612 –1615.
  • 20. Davies E.A., Emmerson A.M., Hogg G.M. An outbreak of infection with methicillin resistant Staphylococcus aureus in a special care baby unit: value of topical mupirocin and of traditional methods of infection control //J.Hosp.Infect.– 1987.– Vol.1.– P.120 –128.
  • 21. De la Brassinne M., de Bersaques J., Vossaert K. Efficacy of mupirocin 2% ointment in skin infections: Belgian prospective open multicentre study //Dermatologica.– 1988.– Vol.177.– P.397 –400.
  • 22. Doebbeling B., Boelart J. Workshop one in staphylococcal infections:proceedings of an advisory workshop //J. Chemother.–1994.– Vol.6,suppl.2.– P.25.
  • 23. Dux P.H., Fields L., Pollock D. 2% topical mupirocin versus systemic erythromycin and cloxacillin in primary and secondary skin infections //Curr.Ther.Res.– 1986.– Vol.40.– P.933 –940.
  • 24. Eells L.D., Mertz P.M., Piovanetti Y. Topical antibiotic treatment of impetigo with mupirocin //Arch.Dermatol. –1986.– Vol.122.– P.1273 –1276.
  • 25. Farmer T.H., Gilbart J., Elson S.W. Biochemical basis of mupirocin resistance in strains of Staphylococcus aureus //J.Antimicrob.Chemother.–1992.–Vol.30.– P.587 –596.
  • 26. Fuchs P.C., Jones R.N., Barry A.L. Interpretative criteria for disc diffusion susceptibility testing of mupirocin, a topical antibiotic //J.Clin.Microbiol.–1990.– Vol.28. –P.608 –609.
  • 27. Fuller A.T., Mellows G., Woodford M.et al. Pseudomonic acid: an antibiotic produced by Pseudomonas fluorescens //Nature.– 1971.–Vol.234.– P.416 –417.
  • 28. Gilbart J., Perry C.R., Slocombe B. High level mupirocin resistance in Staphylococcus aureus:evidence for two distinct isoleucyl tRNA synthetases //Antimicrob.Agent.Chemother.–1993.– Vol.37.–P.32 –38.
  • 29. Gilbert M. Topical 2% mupirocin versus 2% fusidic acidointment in the treatment of primary and secondary skin infections //J.Amer.Acad.Dermatol.–1989.– Vol.20. –P.1083 –1087.
  • 30. Goldfarb J., Grenshaw D., O'Horo J. Randomized clinical trial of topical mupirocin versus oral erythromycin for impetigo //Antimicrob.Agent.Chemother.–1988.– Vol.32.– P.1780 –1783.
  • 31. Gratton D. Topical mupirocin versus oral erythromycinin the treatment of primary and secondary skin infections //Int.J.Dermatol.–1987.– Vol.26.– P.472 –473.
  • 32. Hill L.R., Duckworth G.J., Casewell M.W. Elimination of nasal carriage of methicillin –resistant Staphylococcus aureus with mupirocin during a hospital outbreak //J.Antimicrob.Chemother.– 1988..– Vol..22.– P..377 –384.
  • 33. Hodgson J.E., Curnock S.P., Dyke K.G.H.et al. Molecular characterisation of the gene encoding high level mupirocin resistance in Staphylococcus aureus J2870 //Antimicrob.Agent.Chemother.–1994.– Vol.38.– P.1205 –1208.
  • 34. Hughes J., Mellows G. Inhibition of isoleuciyl transfer ribonucleic acid synthetase in Escherichia coli by pseudomonic acid //Biochem.J.–1978.– Vol.176.– P.305 –318.
  • 35. Hughes J., Mellows G. On the mode of action of pseudomonic acid:inhibition of protein synthesis in Staphylococcus aureus //J.Antibiot.– 1978.– Vol.31.– P.330 –335.
  • 36. Janagisawa T., Lee J.T., Wu H.C., Kawakami M Relationship of protein structure of isoleucyl tRNA synthetase with pseudomonic acid resistance of Escherichia coli. A proposed mode of action of pseudomonic acid as an inhibitor of isoleucyl tRNA synthetase //J.Biol.Chem.–1994.– Vol.269.– P.24304 –24309.
  • 37. Kalmeijer M.D. et al. Perioperative eradication of Nasal Cariage of Staphylococcus aureus by Mupirocin Nasal Ointment (MUP)as prevention of surgical site infections (SSI) in orthopedic surgery.– 39th ICAAC.– 1999.– Abstract 514.– P.591.
  • 38. Kauffman C.A., Terpenning M.S., He X. Attempts to eradicate methicillin resistant Staphylococcus aureus from a long term care facility with use of mupirocin ointment //Amer.J.Med.– 1993.– Vol.94.– P.371 –378.
  • 39. Laterre P.F.et al. Failure of mupirocin and chlorexidine to eradicate methicillin resistant Staphylococcus aureus carriage in an intensive care unit //39th ICAAC.– 1999. –Abstract 1702.– P.636.
  • 40. Leyden J.J. Mupirocin:a new topical antibiotic //Semin.Dermatol.–1987.– Vol.6.– P.48 –54.
  • 41. Leyden J.J. Studies on the safety of Bactroban ointment: potential for contact allergy, contact irritation, phototox icity and photoallergy //R.L.Dobson,J.J.Leyden, W.C.Noble,J.D.Price,ed.Bactroban (Mupirocin). Excerpta Medica Current Clinical Practice Series 16.– 1985.– P.68 –71.
  • 42. McLinn S. Topical mupirocin vs.systemic erythromycin treatment for pyoderma //Pediatr.Infect.Dis.J.– 1988. –Vol.7.– P.785 –790.
  • 43. Muder R.R. Mupirocin and MRSA:current status // Infect.Med.– 1993.– Vol.10.– P.21 –22.
  • 44. Needham C., Rahman M., Dyke K.G., Noble W.C. An investigation of plasmids from Staphylococcus aureus that mediate resistance to mupirocin and tetracycline // Microbiology.– 1994.– Vol.140.– P.2577 –2583.
  • 45. Neu H.C. The use of mupirocin in controlling methicillin resistant Staphylococcus aureus //Infect.Cont.Hosp. Epidemiol.–1990.– Vol.11.– P.11 –12.
  • 46. Nicholas R.O., Berry V., Hunter P.A., Kelly J.A. The antifungal activity of mupirocin //J.Antimicrob.Chemother. –1999.– Vol.43,N 4.–P.579 –582.
  • 47. Orecchio R.M., Mischler T.W.A double blind multiclinic comparative trial of mupirocin topical and its vehicle in the treatment of bacterial skin infections //Curr.Ther.Res.– 1986.– Vol.39.– P.82 –86.
  • 48. Pappa K.A. The clinical development of mupirocin //J.Amer.Acad.Dermatol.–1990.– Vol.22.– P.873-879.
  • 49. Philips L.M., Yogov R., Esterly N.B. The efficacy of mupirocin (pseudomonic acid)in the treatment of pyoderma in children //Pediatr.Emerg.Care.– 1985.– Vol.1.– P.180 –183.
  • 50. Rachman M., Noble W.C., Cookson B.D. Mupirocin resistant Staphylococcus aureus //Lancet.– 1987.– ii.– P.387.
  • 51. Reagan D.R., Doebbeling B.N., Pfaller M.A. Elimination of coincident Staphylococcal aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment //Ann.Intern.Med.– 1991.– Vol.114.– P.101-106.
  • 52. Redheadf R.J., Lamb R.J., Rowsell R.B. The efficacy of calcium mupirocin in the eradication of nasal Staphylococcus aureus carriage //Brit.J.Clin.Pract.– 1991.– Vol.45.– P.252 —254.
  • 53. Rittenhouse S.et al. In vivo activity of two novel pleuromutilin derivates,SB 247386 and SB 268091 //39th ICAAC.– 1999.– Abstract 1702.– P.337.
  • 54. Scully B.E., Briones F., Gu J.W. Mupirocin treatment of nasal staphylococcal colonization //Arch.Intern.Med.– 1992.– Vol.152.– P.363 –366.
  • 55. Sesso R., Barbosa D., Leme I.L.et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter, effect of mupirocin ointment //J.Amer. Soc.Nephrol.–1998.– Vol.9,N 6.–P.1085 –1092.
  • 56. Sutherland R., Boon R.J., Griffin K.E. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use //Antimicrob.Agent Chemother.– 1985.– Vol.27.– P.495 –498.
  • 57. Udo E.E., Jacob L.E., Mokadas E.M. Conjugative transfer of high level mupirocin resistance from Staphylococcus haemolyticus to other staphylococci // Antimicrob.Agent.Chemother.–1997.– Vol.41.– P.693 –695.
  • 58. Vanderbroucke Grauls C.M., Frenay H.M.E., van Klingeren B. Control of epidemic methicillin resistant Staphylococcus aureus in a Dutch university hospital // Eur.J.Clin.Microbiol.Infect.Dis.– 1991.– Vol.10.– P.6 –11.
  • 59. Welsh O., Saenz C. Topical mupirocin compared with oral ampicillin in the treatment of primary and secondary skin infections //Curr.Ther.Res.– 1987.– Vol.41.– P.114 –120.
  • 60. Wuite J., Davies B.I., Go M.J. Pseudomonic acid, a new antibiotic for topical therapy //J.Amer.Acad.Dermatol. –1985.– Vol.12.– P.1026 –1031.
  • 61. Wuite J., Davies B.I., Go M.J. Pseudomonic acid: a new topical antimicrobial agent //Lancet.– 1983.– Vol.2.– P.394.
  • 62. Yangco B.G. Reduction of postoperative Staphylococcus aureus infections in open heart surgery by intranasal mupirocin //39th ICAAC.– 1999.– Abstract 512.– P.591.
Просмотров
0 Аннотация
0 PDF
0 Цитирования
Поделились